88 related articles for article (PubMed ID: 10896234)
1. Humanized severe combined immunodeficient mice as a potential model for the study of tolerance to factor VIII.
Vanzieleghem B; Gilles JG; Desqueper B; Vermylen J; Saint-Remy JM
Thromb Haemost; 2000 Jun; 83(6):833-9. PubMed ID: 10896234
[TBL] [Abstract][Full Text] [Related]
2. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
3. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII.
Hausl C; Maier E; Schwarz HP; Ahmad RU; Turecek PL; Dorner F; Reipert BM
Thromb Haemost; 2002 May; 87(5):840-5. PubMed ID: 12038787
[TBL] [Abstract][Full Text] [Related]
4. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.
Gilles JG; Saint-Remy JM
J Clin Invest; 1994 Oct; 94(4):1496-505. PubMed ID: 7523452
[TBL] [Abstract][Full Text] [Related]
5. Animal models to explore mechanisms of tolerance induction to FVIII: SCID mice and SCID-FVIII-KO mice.
Gilles JG; Vanzieleghem B; Saint-Remy JM
Haematologica; 2000 Oct; 85(10 Suppl):103-6; discussion 106-7. PubMed ID: 11187860
[No Abstract] [Full Text] [Related]
6. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
[TBL] [Abstract][Full Text] [Related]
7. Role of anti-idiotypic antibodies in immune tolerance induction.
Gilles JG
Haemophilia; 2010 May; 16(102):80-3. PubMed ID: 20536989
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
9. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
Scandella D; Reyes H; Felch M; Sakurai Y
Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
[TBL] [Abstract][Full Text] [Related]
10. Restricted epitope specificity of anti-FVIII antibodies that appeared during a recent outbreak of inhibitors.
Gilles JG; Peerlinck K; Arnout J; Vermylen J; Saint-Remy JM
Thromb Haemost; 1997 May; 77(5):938-43. PubMed ID: 9184406
[TBL] [Abstract][Full Text] [Related]
11. Mapping of natural anti-factor VIII antibodies in plasma pools from healthy donors: use of rationally designed synthetic peptides.
Di Giambattista M; Branckaert T; Laub R
Biologicals; 2001; 29(3-4):229-32. PubMed ID: 11851320
[TBL] [Abstract][Full Text] [Related]
12. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
[TBL] [Abstract][Full Text] [Related]
13. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
14. The diversity of antigen-specific antibodies in humans and in two xenochimeric SCID mouse models.
Layer A; Tissot JD; Schneider P; Duchosal MA
Electrophoresis; 2000 Jul; 21(12):2463-75. PubMed ID: 10939460
[TBL] [Abstract][Full Text] [Related]
15. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A.
Reipert BM; Ahmad RU; Turecek PL; Schwarz HP
Thromb Haemost; 2000 Nov; 84(5):826-32. PubMed ID: 11127864
[TBL] [Abstract][Full Text] [Related]
16. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
Kallas A; Kuuse S; Maimets T; Pooga M
Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
[TBL] [Abstract][Full Text] [Related]
17. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII.
Sasgary M; Ahmad RU; Schwarz HP; Turecek PL; Reipert BM
Thromb Haemost; 2002 Feb; 87(2):266-72. PubMed ID: 11858486
[TBL] [Abstract][Full Text] [Related]
18. Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors.
Sakurai Y; Shima M; Tanaka I; Fukuda K; Yoshida K; Yoshioka A
Haematologica; 2004 Jun; 89(6):696-703. PubMed ID: 15194537
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
20. The production and characterisation of a panel of ten murine monoclonal antibodies to human procoagulant factor VIII.
Griffin BD; Micklem LR; McCann MC; James K; Pepper DS
Thromb Haemost; 1986 Feb; 55(1):40-6. PubMed ID: 3085263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
